Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719680 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT00719680 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 21 participants.
The verdict
NCT00719680, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.
Interventions
- BIOLOGICAL IgPro20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719680
The ClinicalTrials.gov registry entry for NCT00719680 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IgPro20 is the first listed.
NCT00719680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719680 about?
NCT00719680 is a clinical study titled "Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)". The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.
What is the current status of trial NCT00719680?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2008-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00719680?
The interventions under investigation include: IgPro20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00719680?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.